News RSS Feed

News RSS Feedhttp://www.bausch.com/en/RSS/News-FeedBausch and Lomb News Feeden{F733AF46-D80D-4278-B4F2-DDE8A0373A32}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Settlement-Resolve-and-Conclude-ISTA-Pharmaceuticals-InvestigationBausch + Lomb Announces Settlement with the U.S. Department of Justice to Resolve and Conclude ISTA Pharmaceuticals InvestigationFri, 24 May 2013 00:00:00 -0400{5839B3DF-BAFA-47C8-BA4C-4CB1D93D2897}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/TrulignBausch + Lomb Receives FDA Approval for the TRULIGN™ Toric Posterior Chamber Intraocular LensTue, 21 May 2013 00:00:00 -0400{34DE4578-FFAE-42DD-B2DB-D05309E0E9BA}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Maria-Teresa-Hilado-Joins-Bausch-Lomb-Board-of-DirectorsMaria Teresa Hilado Joins Bausch + Lomb Board of DirectorsWed, 15 May 2013 00:00:00 -0400{133743BD-0C5F-4E58-9E9E-B1C110B2B800}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Alex-Kelly-Vice-President-Investor-Relations-Bausch-LombAlex Kelly Joins Bausch + Lomb as Vice President Investor RelationsThu, 09 May 2013 00:00:00 -0400{0CEE816A-C69E-4EE9-8BF2-492D129C616C}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/ARVO59Bausch + Lomb Reports Fourth Year of Data on Patterns of Bacterial Resistance in Ocular InfectionsThu, 09 May 2013 00:00:00 -0400{98639AA3-7467-44C5-97C9-B6F2E1F32204}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Incise-Microincision-intraocular-lens-EuropeBausch + Lomb Introduces INCISE® Microincision Intraocular Lens in EuropeThu, 02 May 2013 00:00:00 -0400{D13C3C57-1660-4FBD-836B-9428024689EC}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-MeetingBausch + Lomb to Present Wealth of Data at the Association for Research in Vision and Ophthalmology Annual MeetingWed, 01 May 2013 00:00:00 -0400{F8D77CA6-4F2D-4FE0-98B0-F739DDD597C2}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/PhysIOL-Trifocal-Diffractive-and-Toric-Intraocular-LensesBausch + Lomb to Distribute PhysIOL Trifocal Diffractive and Toric Intraocular Lenses in Key Asian, European and Middle Eastern MarketsWed, 01 May 2013 00:00:00 -0400{90DC2C1C-B88F-4D42-9FDE-1143D077BAB6}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Donald-Gagliano-Global-Development-OperationsFormer Executive Director, Department of Defense and Department of Veterans Affairs Vision Center of Excellence, Joins Bausch + LombFri, 26 Apr 2013 00:00:00 -0400{5BCFE267-1506-4C4E-96BE-2DF047B9C784}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-Agreement-Paragon-BioteckBausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine Fri, 19 Apr 2013 00:00:00 -0400{9F5C775A-8125-4A02-A7AF-8A46BD58771C}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Roundup-ASCRS-Prolensa-Surgical-PortfolioBausch + Lomb Launches PROLENSA™ and Showcases Innovative Additions to its Surgical Product Portfolio at the ASCRS Annual MeetingWed, 17 Apr 2013 00:00:00 -0400{4D820A41-B274-4CBF-A56B-15CE652B3CD0}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Leica-Microsystems-Bausch-Lomb-Sign-Global-Agreement-for-Surgical-Operating-MicroscopesLeica Microsystems and Bausch + Lomb Sign Global Agreement for Surgical Operating MicroscopesTue, 16 Apr 2013 00:00:00 -0400{50CA911E-7B52-4C76-BFB0-909214459674}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/FDA-Approval-for-PROLENSABausch + Lomb Receives FDA Approval for PROLENSA™ (bromfenac ophthalmic solution) 0.07% Mon, 08 Apr 2013 00:00:00 -0400{CCCAE9EC-BD4D-49B9-94EB-A23C6602F034}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/VICTUS-CE-Mark-Approval-Corneal-IncisionVICTUS® Femtosecond Laser Platform Receives CE Mark for Corneal Incisions, Penetrating Keratoplasty and Intrastromal Channel Incisions for Intracorneal Ring SegmentsWed, 03 Apr 2013 00:00:00 -0400{02916D82-BF4D-4387-B3D5-AE3BBF281BA6}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-Registration-Statement-for-Proposed-Initial-Public-OfferingBausch + Lomb Files Registration Statement for Proposed Initial Public OfferingFri, 22 Mar 2013 00:00:00 -0400{3802BDEE-2709-422C-950C-D24E8DF100B5}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-and-Walgreens-Collaborate-to-Heighten-Eye-Health-AwarenessBausch + Lomb and Walgreens Collaborate to Heighten Eye Health AwarenessWed, 13 Mar 2013 00:00:00 -0400{DF3DD81B-1A89-4299-8F9B-C4F91E12EA39}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Phase-2b-results-for-glaucoma-drug-candidate-latanoprostenePresentation of the Phase 2b Results for Glaucoma Drug Candidate Latanoprostene Bunod Wed, 06 Mar 2013 00:00:00 -0500{E0126D91-310F-417E-8A58-5CBE1B6257D0}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/robertbertoliniBausch + Lomb Names Robert Bertolini President and Chief Financial OfficerTue, 26 Feb 2013 00:00:00 -0500{C0C1281D-BCFE-490C-A02F-174F9D1D3735}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-In-Office-Promotion-Movie-Experience-SweepstakesBausch + Lomb Announces In-Office Promotion The “Ultimate Movie Experience Sweepstakes” to Introduce Patients to PureVision®2 and SofLens® Daily Disposable Contact Lenses Thu, 14 Feb 2013 00:00:00 -0500{E3EE6F6E-8CA5-4DAE-B184-74A41FEF883B}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/VICTUS-Femtosecond-Laser-Platform-Receives-510-FDA-ClearanceVICTUS™ Femtosecond Laser Platform from Bausch + Lomb Technolas Receives 510(k) Clearance from FDA for Arcuate Incision ProcedureWed, 13 Feb 2013 00:00:00 -0500{EDCDC38F-88A9-4D7C-8297-2AFEED66C0CA}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-Phase-3-Program-for-Glaucoma-Drug-Candidate-NicoxBausch + Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed from NicoxTue, 29 Jan 2013 00:00:00 -0500{AD64F864-CCD9-4DEF-A4D4-D53FDE37F574}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-Completes-Acquisition-of-Technolas-Perfect-Vision-GmbHBausch + Lomb Completes Acquisition of Technolas Perfect Vision GmbHMon, 28 Jan 2013 00:00:00 -0500{C3391FC0-997E-436A-AC33-5979D4A05302}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Bausch-Lomb-and-CROMA-Donate-Eye-DropsBausch + Lomb and CROMA Donate Urgently-Needed Eye DropsTue, 22 Jan 2013 00:00:00 -0500{06D749D5-7CCD-4A88-9BDC-2040533986F9}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/media-alert-1082013UPDATED MEDIA ALERT: U.K. Eye Drop Recall Tue, 08 Jan 2013 00:00:00 -0500{9C8D74E3-3BA4-4E08-88B3-C4FED55DF714}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/Pharma-Advanced-TechnologyBausch + Lomb Licenses New Technology with Potential to Treat Millions Affected by Ocular RednessMon, 07 Jan 2013 00:00:00 -0500{A6B830F3-F666-4C00-B473-2B66719FA12F}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive/media-alert-1042013MEDIA ALERT: U.K. Eye Drop Recall Fri, 04 Jan 2013 20:52:00 -0500{41A6868D-BFAA-4830-BA93-191B38F86059}http://www.bausch.com/en/Our-Company/Recent-News/2013-Archive2013 Archive{A5A3D201-8F4A-4229-9269-26CD6CA7AF55}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Run-for-Vision27th Annual “Run for Vision” Raises Needed Funds for Eye Bank Association of America to Help Restore Sight Tue, 13 Nov 2012 00:00:00 -0500{A4AEE123-27FA-4E95-B231-6CFA4D63DA8F}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Lotemax-Gel-PharmaciesNew LOTEMAX® (loteprednol etabonate ophthalmic gel) 0.5% in a Gel Drop Formulation Available in Pharmacies January 2013Fri, 09 Nov 2012 00:00:00 -0500{4706CE72-427D-453D-8371-25D6AF4C2899}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/VICTUS-SurgeonLeading US Surgeons Describe Their Experiences With The New VICTUS™ Femtosecond Laser PlatformFri, 09 Nov 2012 00:00:00 -0500{25D95690-EE06-44FE-BCC0-D793D698BE1E}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/AAO-RoundupBausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of OphthalmologyThu, 08 Nov 2012 00:00:00 -0500{81F9D228-01A4-4A54-8C5C-C7E3B89F6706}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Acquire-TechnolasBausch + Lomb to Acquire Technolas Perfect Vision GmbHWed, 07 Nov 2012 00:00:00 -0500{253EEE8E-B17D-4047-8542-9F582E9A301B}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Drive-Away-the-GlareBe Aware and Drive Away the GlareThu, 01 Nov 2012 00:00:00 -0400{AA9D4190-A2D4-4060-859B-0E24DC6BBDFD}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Cirle-Research-PartnershipBausch + Lomb Announces Research Partnership with Cirle Wed, 03 Oct 2012 00:00:00 -0400{B954212E-CAF1-4B64-A0F6-0C5C59352789}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Lotemax-Gel-Drop-FormulationBausch + Lomb Receives FDA Approval of LOTEMAX® (loteprednol etabonate ophthalmic gel) 0.5% Gel Drop Formulation Mon, 01 Oct 2012 00:00:00 -0400{10FAE6D2-95AA-45FE-8FB6-F7898C26126E}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Pediatric-Cataract-Large-Capacity-GrantBausch + Lomb and Lions Clubs International Foundation Award US$150,000 Grant to Siliguri Greater Lions Eye Hospital Wed, 26 Sep 2012 00:00:00 -0400{AB7D974C-94C0-430F-89B5-5AF50C3B51EB}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Besivance-Additional-IndicationsBesivance® (besifloxacin ophthalmic suspension) 0.6% Receives Additional Indications, Including the Treatment of Bacterial Conjunctivitis Infections Due to Pseudomonas aeruginosa Wed, 19 Sep 2012 00:00:00 -0400{266DC2B2-E706-4D23-88B5-4227FFA51DEF}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/enVista-Toric-EuropeBausch + Lomb Introduces enVista® TORIC Intraocular Lens In EuropeMon, 10 Sep 2012 00:00:00 -0400{B8E98F02-0647-4E57-B904-376542AE06E5}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Final-Tender-OfferBausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 ⅞% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)Mon, 20 Aug 2012 00:00:00 -0400{DA8AFBBB-5DE0-4241-9F5D-A47CA39AD1B4}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/FDA-VICTUS-Femtosecond-ApprovalBausch + Lomb and Technolas™ Perfect Vision Receive 510(k) FDA Clearance from FDA for VICTUS™ Femtosecond Laser Platform Mon, 06 Aug 2012 00:00:00 -0400{0A3478B3-1FE7-4979-9582-8C55C74FF542}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Notes-Tender-OfferBausch + Lomb Announces Extension of Early Tender Date for Its Previously Announced Tender Offer for Its 9 ⅞% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)Mon, 06 Aug 2012 00:00:00 -0400{986363B6-5470-4CCA-AA83-F54EF41E633F}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Commences-Tender-OfferBausch + Lomb Commences Tender Offer of Its 9 ⅞% Senior Notes due 2015 (CUSIP Nos. 071707AN3 and U07190AA6)Mon, 23 Jul 2012 00:00:00 -0400{98745EE6-1B57-4173-B0D9-F4E5D7709BFF}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/BarometerGlobally, We Are Losing Sight of Our Eye Health, a New Public Opinion Poll Reveals Wed, 18 Jul 2012 00:00:00 -0400{4B358499-3BCA-4FC6-BD90-78386DF86452}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/renu-AnniversaryBausch + Lomb Celebrates 25th Anniversary of renu® Multi-Purpose Solution BrandFri, 29 Jun 2012 00:00:00 -0400{8FD4088A-00B8-4524-98CA-000CBB8156EE}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/US-Approval-Biotrue-ONEday-ContactsBausch + Lomb Receives US FDA Clearance for Biotrue™ ONEday Contact LensesThu, 28 Jun 2012 00:00:00 -0400{8129783B-7B1B-450A-8455-1C6B52301A5E}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Approval-Envista-IOLBausch + Lomb Receives FDA Approval of the enVista™ Intraocular Lens Wed, 20 Jun 2012 00:00:00 -0400{1327A63A-8ECA-42AC-9B84-49E33A5B4FC1}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/New-Drug-Application-for-Once-Daily-PROLENSABausch + Lomb Submits New Drug Application for Once-Daily PROLENSA™ to Treat Ocular Inflammation and Pain Following Cataract SurgeryMon, 18 Jun 2012 00:00:00 -0400{0F002FC6-6057-40A5-839B-0F14F8B9EB51}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Acquisition-Completed-ISTABausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals Wed, 06 Jun 2012 00:00:00 -0400{DFDC9AE2-8073-4B19-9A7D-72B7A9900F94}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Biotrue-ONEday-Contact-LensesBausch + Lomb Launches Biotrue™ ONEday Contact Lenses Made From Breakthrough HyperGel™ Material Fri, 25 May 2012 00:00:00 -0400{FDA91E0C-06C1-4AEC-9E3C-4E909BB8F4BC}http://www.bausch.com/en/Our-Company/Recent-News/2012-Archive/Bausch-Lomb-Opens-Philippine-OfficeBausch + Lomb Opens Philippine Office to Deliver Eye Health Solutions to Doctors and PatientsTue, 22 May 2012 00:00:00 -0400